Navigation Links
Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
Date:5/22/2013

tein degradation.   Daiichi Sankyo has brought a small molecule from this collaboration, through preclinical development, recently filed an IND, and intends to begin a Phase 1 clinical study of the orally bioavailable study drug, which is aimed at targeting ubiquitin protein ligase. Since dysfunction in the ubiquitin/proteasome system has been shown to be associated with cancer, selective small molecules targeting ubiquitin ligases may be a novel approach to treatment.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for RA with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which are undergoing Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor, expected to enter into a Phase 2 clinical trial for the treatment of chronic dry eye. 

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy, its programs in dry eye and oncology, and the further development of, and the therapeutic and commercial potential of fostamatinib, partnered with AstraZeneca.   Any statements contained in this press release th
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
7. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
8. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LONDON , April 21, 2015 ... for Enterprise, having achieved dazzling export-led growth in ... London™ today celebrates its part in winning the ... International Trade, awarded to Oxford PharmaGenesis. As part ... London helps its clients bring new medicines to ...
(Date:4/21/2015)... -- This report analyzes the worldwide markets for Apheresis ... for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global ... Plateletpheresis, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Annual estimates and forecasts are provided for the period ...
(Date:4/21/2015)... -- Cardiologists at Henry Ford Hospital have implanted a device ... irregular heartbeat. With only handful of hospitals in ... able to add another option to its arsenal of tools ... ability to pump. "This is a first ... implant at a non-clinical trial site," says cardiologist Claudio ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Fast-growing London Consultancy 2Queen's Award Crowns Achievements of Fast-growing London Consultancy 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 4Queen's Award Crowns Achievements of Fast-growing London Consultancy 5World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 Top medical ... in India for their ongoing commitment to providing superior ... strives to provide patients with the best possible experience ... skin, hair and body. , Executives at Ojas Aesthetic ... the philosophy of — nothing about you, without you ...
(Date:4/21/2015)... Jersey City, NJ (PRWEB) April 21, 2015 ... enterprise collaboration across platforms and devices, today announced a ... the integration of the new Microsoft Office 365 Management ... that allows customers to fully audit and take action ... 365 environments. , “The new Office 365 Management Activity ...
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Edward ... and Arthur “A.G.” Kawamura, former Secretary of the California ... featured speakers for the 2nd Annual GrowRIVERSIDE Conference: The ... , The inclusion of these nationally known experts ... experts, city planners, farmers and others slated to speak ...
(Date:4/21/2015)... Further strengthening ties between the two institutions, ... goods and services to the University of South Florida ... BRIDGE Healthcare Clinic. , The BRIDGE clinic – a ... year – provides primary medical care to more than ... inside the USF Health Morsani Center for Advanced Healthcare. ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... the insulin gene to diabetes patients using nanoparticles, was presented ... Society of Gene Therapy (ASGT) in Seattle. ,Type ... the insulin producing pancreatic -cells. As a result of the ... damage to fine blood vessels and nerve endings leading to ...
... with culture-positive tuberculosis (TB), relapse rates were found ... compared to HIV-uninfected patients following a rifamycin-based regimen. ... patients who received intermittent or standard 6-month therapy ... treatment. ,The results appear in the ...
... But one should pop the pill just before sex. The ... good news for those suffering from erectile dysfunction (ED) - ... than the pills. ,Human and animal trials suggest ... treatments available. A University of Pittsburgh team, led by Dr ...
... CHICAGO:- Scientific advances have enabled better diagnosis and treatment ... presented at the world's premier conference on cancer. "We've ... unique to women," Julie Gralow, assistant professor of oncology ... ,"The studies discussed today bring us even closer ...
... CHICAGO, Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, ... extended overall survival in patients with hepatocellular ... taking placebo by 44%. Results were presented at ... of Clinical Oncology (ASCO). ,The international, ...
... new climate plan of the US should complement rather than ... Climate Change (UNFCCC), China's top economic planner Ma Kai ... common but differentiated responsibilities in the UNFCCC and some details ... other countries, Ma said at a press conference. ...
Cached Medicine News:Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Health News:Gene Therapy a Better Alternative to Viagra Please 2Health News:Advanced Scientific Brings Help for Breast Cancer Survivors 2Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
Medicine Products: